Advances in prostate cancer imaging [version 1; referees: 3 approved]

Many exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound an...

Full description

Bibliographic Details
Main Authors: Matthew R. Tangel, Ardeshir R. Rastinehad
Format: Article
Language:English
Published: F1000 Research Ltd 2018-08-01
Series:F1000Research
Online Access:https://f1000research.com/articles/7-1337/v1
id doaj-ff45b5c4a0af42a283774a9e75555a30
record_format Article
spelling doaj-ff45b5c4a0af42a283774a9e75555a302020-11-25T03:51:03ZengF1000 Research LtdF1000Research2046-14022018-08-01710.12688/f1000research.14498.115783Advances in prostate cancer imaging [version 1; referees: 3 approved]Matthew R. Tangel0Ardeshir R. Rastinehad1Department of Radiology, Mount Sinai Health System, New York, NY, 10003, USADepartment of Interventional Radiology, Mount Sinai Health System, New York, NY, 10003, USAMany exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound and shear wave elastography may be strong alternatives in patients who cannot undergo MRI. Prostate-specific membrane antigen-directed positron emission tomography/computed tomography has proven to be valuable in the primary staging of high-risk disease and for detecting disease in patients with biochemical recurrence. As more studies continue to emerge, it is becoming clear that the standard algorithm for diagnosing and staging prostate cancer will undergo significant changes in the near future.https://f1000research.com/articles/7-1337/v1
collection DOAJ
language English
format Article
sources DOAJ
author Matthew R. Tangel
Ardeshir R. Rastinehad
spellingShingle Matthew R. Tangel
Ardeshir R. Rastinehad
Advances in prostate cancer imaging [version 1; referees: 3 approved]
F1000Research
author_facet Matthew R. Tangel
Ardeshir R. Rastinehad
author_sort Matthew R. Tangel
title Advances in prostate cancer imaging [version 1; referees: 3 approved]
title_short Advances in prostate cancer imaging [version 1; referees: 3 approved]
title_full Advances in prostate cancer imaging [version 1; referees: 3 approved]
title_fullStr Advances in prostate cancer imaging [version 1; referees: 3 approved]
title_full_unstemmed Advances in prostate cancer imaging [version 1; referees: 3 approved]
title_sort advances in prostate cancer imaging [version 1; referees: 3 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2018-08-01
description Many exciting advances in medical imaging have been made in recent years that will alter the way we diagnose, stage, and treat patients with prostate cancer. Multiparametric magnetic resonance imaging (MRI) is emerging as the main modality for prostate cancer imaging. Contrast-enhanced ultrasound and shear wave elastography may be strong alternatives in patients who cannot undergo MRI. Prostate-specific membrane antigen-directed positron emission tomography/computed tomography has proven to be valuable in the primary staging of high-risk disease and for detecting disease in patients with biochemical recurrence. As more studies continue to emerge, it is becoming clear that the standard algorithm for diagnosing and staging prostate cancer will undergo significant changes in the near future.
url https://f1000research.com/articles/7-1337/v1
work_keys_str_mv AT matthewrtangel advancesinprostatecancerimagingversion1referees3approved
AT ardeshirrrastinehad advancesinprostatecancerimagingversion1referees3approved
_version_ 1724489092765319168